This pioneering medical technology company is at the forefront of photobiomodulation—a clinically supported, non-pharmacological treatment revolutionizing pain management and recovery. Its FDA-registered, Class II medical device is backed by over 600 double-blind studies and used by more than 6,000 individuals, including elite athletes, military personnel, and healthcare professionals. The device is currently under evaluation by the NFL for its potential to help prevent and treat traumatic brain injuries.
Since 2017, the company has played a critical role in addressing the opioid crisis by offering a proven, drug-free alternative for managing chronic pain. Its light therapy solution is now gaining approval from a growing number of medical providers and is being accepted by major insurance carriers. With a nationwide expansion underway, the company currently operates seven clinics with three more opening this quarter and is scaling through a franchise model.
The owners are seeking a $10 million dollar investment via a 7-year note at 2% above prime. Any unpaid balance at maturity, including interest, will convert to equity at a 20% post-money discount. Equity of up to 10% in the company is available to qualified investors.
A full investor deck is available upon request, pending execution of a non-disclosure agreement and submission of a financial profile.
ASKING INVESTMENT: The owners are seeking an investment of $10,000,000, for a 7-year note at 2% above prime interest rate. Amounts, including interest, not paid in full by maturity date convert to equity at post-money 20% discount. Equity in the company of up to 10% available.
GROSS SALES: $4,650,000
EMPLOYEES: 16